Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

anlotinib 5Cisplatin 5Carboplatin 5Immune Checkpoint Inhibitors 4tislelizumab 3sintilimab 3lenvatinib 3Oxaliplatin 3Fluorouracil 3Capecitabine 3Bevacizumab 3venetoclax 2Rosuvastatin Calcium 2Prednisone 2Megestrol Acetate 2Leucovorin 2Gemcitabine 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Aspirin 2zanubrutinib 1xiaojin wan 1trastuzumab deruxtecan 1trametinib 1toripalimab 1tocilizumab 1testosterone 17 beta-cypionate 1tenofovir alafenamide 1telitacicept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × naxitamab × Clear all
NCT06047535 2023-09-21

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

SciClone Pharmaceuticals

Phase 4 Not yet recruiting
62 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡